Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer

Plain-language summary

This study evaluates the real-life use of the Endopredict test in early-stage, hormone receptor-positive, HER2-negative breast cancer. Patients with this type of breast cancer, for whom clinical criteria alone are not enough to decide on the need for additional chemotherapy after breast surgery, can take part. It is a study without an assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Assistance Publique - Hôpitaux de Paris

Intervention

Endopredict test

Start date

6/28/2026

Estimated completion

6/28/2031

Countries

France

Related genes

Locations

• Paris, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patient with early breast cancer, hormone receptor-positive, HER2 non-amplified, for whom clinical criteria are deemed insufficient to determine the need for adjuvant chemotherapy, combined with hormone therapy, after breast surgery.

Exclusion Criteria:

* Patients who did not undergo testing or whose test results were not validated